Cue Biopharma, Inc. (CUE)
 NASDAQ: CUE · Real-Time Price · USD
 0.6994
 +0.0094 (1.36%)
  Oct 30, 2025, 4:00 PM EDT - Market closed
Cue Biopharma Revenue
Cue Biopharma had revenue of $2.95M in the quarter ending June 30, 2025, with 11.14% growth. This brings the company's revenue in the last twelve months to $8.29M, down -0.11% year-over-year. In the year 2024, Cue Biopharma had annual revenue of $9.29M with 69.16% growth.
Revenue (ttm) 
 $8.29M
Revenue Growth 
 -0.11%
P/S Ratio 
 6.23
Revenue / Employee 
 $202,098
Employees 
 41
Market Cap 
53.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 9.29M | 3.80M | 69.16% | 
| Dec 31, 2023 | 5.49M | 4.25M | 340.96% | 
| Dec 31, 2022 | 1.25M | -13.70M | -91.67% | 
| Dec 31, 2021 | 14.94M | 11.79M | 373.68% | 
| Dec 31, 2020 | 3.15M | -304.01K | -8.79% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Eli Lilly and Company | 53.26B | 
| Novo Nordisk | 49.11B | 
CUE News
- 4 weeks ago - Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates - GlobeNewsWire
- 2 months ago - Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme - GlobeNewsWire
- 2 months ago - Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 3 months ago - Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer - GlobeNewsWire
- 4 months ago - Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies - GlobeNewsWire
- 4 months ago - Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease - GlobeNewsWire
- 6 months ago - Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire